Valneva SE's Total Assets for the quarter that ended in Mar. 2026 was $430.1 Mil.
During the past 12 months, Valneva SE's average Total Assets Growth Rate was -19.00% per year.
During the past 3 years, the average Total Assets Growth Rate was -4.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -0.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 8.00% per year.
During the past 13 years, Valneva SE's highest 3-Year average Total Assets Growth Rate was 79.60%. The lowest was -13.20%. And the median was 19.10%.
Total Assets is connected with ROA %. Valneva SE's annualizedROA % for the quarter that ended in Mar. 2026 was -33.07%. Total Assets is also linked to Revenue through Asset Turnover. Valneva SE's Asset Turnover for the quarter that ended in Mar. 2026 was 0.08.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Valneva SE's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Valneva SE Total Assets Related Terms
Valneva SE Total Assets Historical Data
* Premium members only.
The historical data trend for Valneva SE's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Valneva SE's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valneva SE (INRLF) has a Total Assets of $430.1 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Valneva SE and its competitors.
Is Valneva SE's Total Assets too high?
Valneva SE's current Total Assets is $430.1 Mil. Overall, Valneva SE has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's Total Assets compare to VRTX and REGN?
Valneva SE's Total Assets of $430.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Valneva SE and its competitors. Valneva SE's current Total Assets is $430.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.84, compared to a current price of $2.62 — trading 7.7% below its estimated fair value. The current Total Assets is $430.1 Mil. Valneva SE's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Valneva SE (INRLF), the current Total Assets is $430.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valneva SE (INRLF) Overvalued in 2026?
Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued.
The current stock price of $2.62 is trading 7.7% below its estimated GF Value™ of $2.84.
GuruFocus considers Valneva SE to be Fairly Valued.
Key valuation signals for INRLF:
Total Assets: $430.1 Mil
GF Value™: $2.84 vs. price of $2.62 (7.7% below fair value)
No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
60GF Score
Get the complete analysis for INRLF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INRLF has been successfully added to your 
